Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study.
Eleven patients with DSM-III-R major depression who were treatment-resistant to sertraline were allocated for lithium augmentation therapy. In conjunction with their sertraline, 6 received lithium carbonate 400 mg at night and 5 received 800 mg at night. A total of 7 patients responded within 1 week. The degree of response was not related to the serum lithium level. Patients with lithium levels as low as 0.3 mEq/l responded. No significant side effects were reported.
Dinan
T G
TG
Department of Psychological Medicine, St Bartholomew's Hospital, London, United Kingdom.
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline
D015057:1-Naphthylamine; D000928:Antidepressive Agents; D016651:Lithium Carbonate; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline